

## SEZ6L RABBIT PAB

**Cat.#:** S220903

**Product Name:** Anti-SEZ6L Rabbit Polyclonal Antibody

**Synonyms:**

**UNIPROT ID:** Q9BYHI (Gene Accession - NP\_066938 )

**Background:** Predicted to act upstream of or within adult locomotory behavior; nervous system development; and regulation of protein kinase C signaling. Predicted to be located in endoplasmic reticulum and neuronal cell body.

**Immunogen:** Synthetic peptide of human SEZ6L

**Applications:** ELISA, WB, IHC

**Recommended Dilutions:** IHC: 50-200;WB: 1000-5000;ELISA: 5000-10000

**Host Species:** Rabbit

**Clonality:** Rabbit Polyclonal

**Isotype:** Immunogen-specific rabbit IgG


**Purification:** Antigen affinity purification

**Species Reactivity:** Human, Mouse


**Constituents:** PBS (without Mg<sup>2+</sup> and Ca<sup>2+</sup>), pH 7.4, 150 mM NaCl, 0.05% Sodium Azide and 40% glycerol

**Research Areas:** Cancer, Neuroscience


**Storage & Shipping:** Store at -20°C. Avoid repeated freezing and thawing




Immunohistochemistry analysis of paraffin embedded Human breast cancer tissue using 220903(SEZ6L Antibody) at a dilution of 1/50(Cytoplasm).




In comparison with the IHC on the left, the same paraffin-embedded Human breast cancer tissue is first treated with the synthetic peptide and then with 220903(Anti-SEZ6L Antibody) at dilution 1/50.



The image on the left is immunohistochemistry of paraffin-embedded Human cervical cancer tissue using 220903(Anti-SEZ6L Antibody) at a dilution of 1/50.



In comparison with the IHC on the left, the same paraffin-embedded Human cervical cancer tissue is first treated with synthetic peptide and then with D262196(Anti-SEZ6L Antibody) at dilution 1/50.



Gel: 6%SDS-PAGE, Lysate: 40 µg;  
 Lane 1-2: HeLa and RAMOS cell lysates;  
 Primary antibody: 220903(SEZ6L Antibody) at dilution 1/1000;  
 Secondary antibody: HRP-conjugated Goat anti rabbit IgG at 1/5000 dilution;  
 Exposure time: 1 minute



# Product Description

Pioneering GTPase and Oncogene Product Development since 2010

---